Integrated BioPharma Reports Results for its Quarter Ended March 31, 2025

Rhea-AI Summary

Integrated BioPharma (OTCQX:INBP) reported strong financial results for Q3 2025. Revenue increased 6.1% to $13.9 million compared to $13.1 million in Q3 2024. The company's operating income rose to $0.7 million from $0.4 million year-over-year. For the nine-month period, revenue grew 6.9% to $40.2 million, with operating income of $1.4 million compared to a loss of $0.2 million in the previous year. Net income for Q3 2025 reached $0.6 million ($0.02 per share), up from $0.3 million ($0.01 per share) in Q3 2024. The company's Contract Manufacturing Segment showed strong performance, with its two largest customers accounting for 83% of total revenue in the nine-month period, down from 90% in the previous year, indicating successful customer base expansion.

Positive

• Revenue growth of 6.1% YoY in Q3 2025
• Operating income increased to $0.7M from $0.4M YoY
• Net income doubled to $0.6M in Q3 2025 from $0.3M in Q3 2024
• Successfully expanded customer base, reducing concentration risk from top customers (83% vs 90%)
• Turned around nine-month operating loss of $0.2M to $1.4M profit

Negative

• High customer concentration with two clients representing 83% of revenue
• Relatively modest profit margins with $0.02 EPS

HILLSIDE, NJ / ACCESS Newswire / May 14, 2025 / Integrated BioPharma, Inc. ((OTCQX:INBP)) (the "Company" or "INBP") reports its financial results for the quarter ended March 31, 2025.

Revenue for the quarter ended March 31, 2025 was $13.9 million compared to $13.1 million for the quarter ended March 31, 2024, an increase of $0.8 million or 6.1%. The Company had operating income in the quarter ended March 31, 2025 of approximately $0.7 million compared to $0.4 million in the quarter ended March 31, 2024.

Revenue for the nine-month period ended March 31, 2025 was $40.2 million compared to $37.6 million for the nine-month period ended March 31, 2024, an increase of $2.6 million or 6.9%. The Company had operating income for the nine-month period ended March 31, 2025 of approximately $1.4 million and an operating loss of approximately $0.2 million for the nine-month period ended March 31, 2024.

For the quarters ended March 31, 2025 and 2024, the Company had net income of approximately $0.6 million and $0.3 million, respectively. The Company's net income per share of common stock and diluted net income per share of common stock for the quarters ended March 31, 2025 and 2024 were $0.02 and $0.01 per share of common stock, respectively.

For the nine-month periods ended March 31, 2025 and 2024, the Company had net income of approximately $1.0 million and a net loss of approximately $0.2 million, respectively. The Company's net income (loss) per share of common stock and diluted net income (loss) per share of common stock for the nine months ended March 31, 2025 and 2024 were $0.03 and $(0.01), respectively.

"Our revenues increased by 6.9% in the nine months ended March 31, 2025 compared to the comparable period a year ago. Our revenue from our two largest customers in our Contract Manufacturing Segment represented approximately 83% and 90% of total revenue in the nine-month period ended March 31, 2025 and 2024, respectively," stated the Co-Chief Executive Officers of the Company, Riva Sheppard and Christina Kay. "We are happy to report that while focusing on our core business we were able to expand our customer base over the past year and increase our revenue," the Co-CEOs further stated.

 

A summary of our financial results for the three months and nine months ended March 31, 2025 and 2024 follows:

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except share and per share amounts)
(Unaudited)

		Three Months Ended								Nine Months Ended
		March 31,								March 31,
		2025				2024				2025				2024
Total revenue		$	13,947			$	13,147			$	40,178			$	37,571
Cost of sales			12,396				11,899				36,085				34,971
Gross profit			1,551				1,248				4,093				2,600
Selling and administrative expenses			812				893				2,662				2,751
Operating income (loss)			739				355				1,431				(151	)
Other income (expense), net			39				(3	)			36				5
Income (loss) before income taxes			778				352				1,467				(146	)
Income tax expense, net			167				67				481				10
Net income (loss)		$	611			$	285			$	986			$	(156	)
Net income (loss) per share:
Basic		$	0.02			$	0.01			$	0.03			$	(0.01	)
Diluted		$	0.02			$	0.01			$	0.03			$	(0.01	)
Weighted average common shares outstanding:
Basic			30,300,720				30,099,610				30,190,869				30,054,883
Diluted			31,514,591				30,744,222				30,960,916				30,054,883

About Integrated BioPharma Inc. (INBP)

Integrated BioPharma, Inc. ("INBP") is engaged primarily in the business of manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. Further information is available at ir.ibiopharma.com.

This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, as well as assumptions, that, if they never materialize or prove incorrect, could cause the results of INBP to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements generally are identified by the words "expects," "anticipates," believes," intends," "estimates," "should," "would," "strategy," "plan" and similar expressions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements and are not guarantees of future performance. Such statements speak only as of the date hereof, are subject to change and should not be relied upon for investment purposes. INBP undertakes no obligation to revise or update any statements for any reasons. The risks, uncertainties and assumptions include, among others, changes in general economic and business conditions; loss of market share through competition; introduction of competing products by other companies; the timing of regulatory approval and the introduction of new products by INBP; changes in industry capacity; pressure on prices from competition or from purchasers of INBP's products; regulatory changes in the pharmaceutical manufacturing industry and nutraceutical industry; regulatory obstacles to the introduction of new technologies or products that are important to INBP; availability of qualified personnel; the loss of any significant customers or suppliers; inflation, including inflationary pressures from any tariffs, and tightened labor markets; our ability to expand our customer base and other risks and uncertainties described in the section entitled "Risk Factors" in INBP's most recent Annual Report on Form 10-K and its subsequent Quarterly Reports on Form 10-Q. Accordingly, INBP cannot give assurance that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on the results of operations or financial condition of INBP.

Contact:
Dina Masi, CFO
Integrated BioPharma, Inc.
investors@ibiopharma.com
888.319.6962

SOURCE: Integrated BioPharma, Inc.

View the original press release on ACCESS Newswire

FAQ

What was Integrated BioPharma's (INBP) revenue in Q3 2025?

Integrated BioPharma reported revenue of $13.9 million in Q3 2025, a 6.1% increase from $13.1 million in Q3 2024.

How much did INBP earn per share in Q3 2025?

INBP earned $0.02 per share in Q3 2025, doubling from $0.01 per share in Q3 2024.

What percentage of INBP's revenue comes from its top customers?

INBP's two largest customers in the Contract Manufacturing Segment represented approximately 83% of total revenue in the nine-month period ended March 31, 2025.

How much operating income did INBP generate in Q3 2025?

INBP generated operating income of $0.7 million in Q3 2025, up from $0.4 million in Q3 2024.

What was INBP's net income for the nine months ended March 31, 2025?

INBP reported net income of $1.0 million for the nine months ended March 31, 2025, compared to a net loss of $0.2 million in the same period of 2024.